세계의 액체생검 시장 : 바이오마커, 샘플, 유형, 기술, 적응증, 최종사용자, 용도별 - 예측(2025-2030년)

The Liquid Biopsy Market was valued at USD 6.00 billion in 2023 and is projected to grow to USD 6.72 billion in 2024, with a CAGR of 12.19%, reaching USD 13.44 billion by 2030.

Liquid biopsy has fundamentally redefined the landscape of diagnostic testing and personalized patient care. Over recent years, innovations in non-invasive diagnostics have set the stage for transformative change in how diseases, particularly cancer, are detected and monitored. This method, which relies on sampling and analyzing non-solid biological tissue, primarily blood, offers a viable alternative to traditional surgical biopsies. The evolution of liquid biopsy technology is driven by its ability to capture circulating biomarkers that provide real-time information about the disease state, enabling timely and targeted therapeutic interventions.

The scientific community has shown an increasing interest in leveraging this technique to overcome the limitations of conventional tissue biopsy, enhancing early detection and facilitating ongoing monitoring. With growing investment in research and development and the integration of high-precision analytical tools, the liquid biopsy market now stands at the convergence of clinical need and technological advancement. In addition to its applications in oncology, liquid biopsy is rapidly expanding its footprint into other areas of medicine, enabling more comprehensive diagnostic solutions. This analysis provides an in-depth look into the current state of the market, elucidating the trends, segmentation, regional insights, and major players who are driving this innovation forward.

Transformative Shifts in the Landscape of Liquid Biopsy

The liquid biopsy market is witnessing rapid transformation fueled by advancements in technology, evolving regulatory frameworks, and increasing demand for minimally invasive diagnostic procedures. Over the past few years, there has been a distinct shift away from traditional methods towards solutions that offer greater precision, faster turnaround times, and broader applicability. Improvements in high-throughput sequencing, data analytics, and automation have not only enhanced the sensitivity and specificity of test results but also made the procedures more cost-effective.

Industry stakeholders are embracing these changes as they seek to leverage the ability of liquid biopsies to capture dynamic genetic and epigenetic alterations. This shift is marked by proactive collaborations between research institutions, technology providers, and healthcare practitioners aimed at refining biomarker discovery and validation processes. Moreover, streamlined regulatory pathways have further accelerated the introduction of novel tools and assays into the clinical setting. As market adoption expands, so too does the competitive landscape, leading to an environment where continuous innovation and integration of multi-disciplinary expertise remain essential. The current momentum surrounding liquid biopsy illustrates a broader trend of adopting precision medicine as a standard practice in clinical diagnostics, ultimately contributing to improved patient outcomes and cost efficiencies across healthcare systems.

Key Segmentation Insights for a Nuanced Market Overview

A detailed segmentation of the liquid biopsy market reveals an intricate structure that supports a diversified approach to disease detection and management. One of the core dimensions of the analysis is based on biomarkers, which underscores the importance of Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles. This biomarker-based segmentation not only highlights the varied diagnostic capabilities but also emphasizes the specific molecular insights that each marker provides. Equally important is the segmentation based on sample type. The market is studied across methodologies that utilize Blood Based and Urine Based samples, supporting both convenience and clinical effectiveness.

Furthermore, the market is categorized by the type of products and services offered, encompassing Assay Kits, Instruments, and Services, each playing a unique role in driving diagnostic performance. Equally significant is the segmentation based on technology, which leans on advanced platforms such as Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays. The segmentation further differentiates applications by indication, distinguishing between Cancer Indication and Non-Cancer Indication. In the cancer segment, sub-classifications include prevalent conditions such as Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer, each requiring specific diagnostic attention. Other dimensions focus on end-user environments, ranging from Academic & Research Centers to Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories. Finally, the application segmentation covers processes such as Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring, all of which collectively underpin a comprehensive patient management strategy.

Based on Biomarkers, market is studied across Cell-free DNA, Circulating Tumor Cells, Circulating Tumor DNA, and Extracellular Vesicles.

Based on Sample, market is studied across Blood Based and Urine Based.

Based on Type, market is studied across Assay Kits, Instruments, and Services.

Based on Technology, market is studied across Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays.

Based on Indication, market is studied across Cancer Indication and Non-Cancer Indication. The Cancer Indication is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer.

Based on End-User, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, Hospitals, and Physician's Office Laboratories.

Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.

Key Regional Insights Shaping Market Dynamics

Geographical analysis reveals distinctive growth patterns and market dynamics across different regions. In the Americas, high healthcare expenditure and advanced technological adoption in diagnostic practices have fostered rapid market growth and innovation. The region has been instrumental in validating cutting-edge approaches to liquid biopsy, driven by a synergistic ecosystem of research institutions, biotech companies, and regulatory support.

In the combined region of Europe, Middle East & Africa, the market benefits from robust public healthcare systems and collaborative research efforts that bridge technology with clinical practice. Firms in these regions are increasingly investing in the development of assays and platforms tailored to local healthcare needs, thereby enhancing diagnostic access and efficacy. Asia-Pacific stands out as a key growth driver, with emerging economies spearheading investment in healthcare infrastructure and diagnostic technologies. Government initiatives and rapidly expanding insurance coverage are further catalyzing market expansion. Cultural shifts towards early disease detection, combined with increased awareness and adoption of preventive healthcare measures, are expected to propel this region into a leading market segment over the coming years. Such geographical diversity highlights the regional nuances that collectively contribute to the global narrative of the liquid biopsy revolution.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Steering Innovation and Competition

The competitive landscape in the liquid biopsy market is characterized by a blend of established industry giants and nimble innovators. Prominent market players such as ANGLE PLC, Bio-Rad Laboratories, Inc., and Bio-Techne Corporation have cemented their roles by continuously investing in new technologies and expanding their product portfolios. Biocartis NV and Danaher Corporation, along with DiaCarta, Inc. and Dxcover Limited, are also pivotal in driving forward the diagnostic capabilities of liquid biopsy through strategic collaborations and cutting-edge research.

Epic Sciences Inc. and Exact Sciences Corporation have distinguished themselves by developing assays that offer high sensitivity and specificity, thereby setting benchmarks for clinical outcomes. F. Hoffmann-La Roche Ltd. and GENCURIX have leveraged their extensive experience in diagnostics to integrate liquid biopsy into broader therapeutic management frameworks. Companies such as Guardant Health, Inc. and Illumina, Inc. are renowned for their state-of-the-art sequencing technologies, which have significantly advanced the liquid biopsy field. The market is further enriched by contributions from Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, and Lucence Health Inc., whose innovative solutions drive process improvements in sample analysis. LungLife AI, Inc. and MDxHealth SA are actively involved in the development of artificial intelligence tools that further enhance diagnostic precision, while players like Menarini Silicon Biosystems SpA, Merck KGaA, and Myriad Genetics, Inc. maintain strong research pipelines. Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc. round out the competitive spectrum by contributing critical research, robust analytical frameworks, and dynamic market strategies that collectively propel the industry toward sustained innovation and global influence.

The report delves into recent significant developments in the Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include ANGLE PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocartis NV, Danaher Corporation, DiaCarta, Inc., Dxcover Limited, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENCURIX, Guardant Health, Inc., Illumina, Inc., Labcorp Holdings Inc., Laboratory Dr. med. Pachmann, Lucence Health Inc., LungLife AI, Inc., MDxHealth SA, Menarini Silicon Biosystems SpA, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., NeoGenomics Laboratories, Inc., OncoDNA SA, PerkinElmer, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics AB, Strand Life Sciences Pvt Ltd., Sysmex Corporation, Tempus AI, Inc., and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to invest in furthering diagnostic research and technological innovation while integrating cross-functional collaboration with clinical practitioners to boost validation studies. Active engagement in strategic partnerships with both academia and technology developers will ensure that emerging trends and regulatory changes are effectively leveraged to maintain competitive advantage. Emphasis should be placed on diversifying product suites to include next-generation sequencing platforms and advanced amplification tools that cater to evolving market needs. Furthermore, leaders must continuously evaluate supply chain efficiencies and streamline operational processes to reduce time-to-market for new diagnostic tools. Adoption of digital analytics and data management solutions can also play a pivotal role in optimizing clinical decision-making and improving patient outcomes. By staying abreast of technological advancements and regional market trends, companies can secure a leading position in a rapidly evolving landscape.

Conclusion: Charting the Course for Future Success

In summary, the liquid biopsy market represents a dynamic intersection of technological innovation and clinical application. The comprehensive insights provided, categorized by biomarkers, sample types, product offerings, technologies, indications, end-user environments, and applications, underscore the evolving nature of diagnostics in the modern medical landscape. Regional and competitive analyses further highlight that success in this arena depends on the ability to integrate cutting-edge science with strategic execution. As the market continues to mature, ongoing innovation and adaptive strategies will be crucial in meeting the challenges of evolving disease profiles and regulatory environments. This analysis reaffirms that a proactive, research-driven approach remains central to leveraging the full potential of liquid biopsy applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer worldwide necessitating early diagnosis methods
    • 5.1.1.2. Supportive government initiatives and policies for the adoption of non-invasive diagnostic tools
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with low abundance and fragile nature of the circulating tumor cells
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of funding to expand cancer research in the field of liquid biopsy
    • 5.1.3.2. Significant use of microarrays and next-generation sequencing (NGS)
  • 5.1.4. Challenges
    • 5.1.4.1. Data privacy concerns and ethical issues in liquid biopsy technology
• 5.2. Market Segmentation Analysis
  • 5.2.1. Biomarkers: Significant utilization of cell-free DNA (cfDNA) versatile in identifying genetic changes
  • 5.2.2. Sample: Rising usage of blood-based liquid biopsies owing to their broad clinical applications and robust data support
  • 5.2.3. Type: Evolving usage of assay kits for early detection and screening of cancer symptoms
  • 5.2.4. Technology: Increasing preference for the multi-gene parallel analysis using next-generation sequencing (NGS), offering higher throughput data
  • 5.2.5. Indication: Burgeoning preference for liquid biopsy tests for breast cancer due to its high prevalence
  • 5.2.6. End-User: Proliferating usage of the liquid biopsy test across the clinical diagnostic laboratories
  • 5.2.7. Application: Exponential utilization of the liquid biopsy for early cancer screening
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liquid Biopsy Market, by Biomarkers

• 6.1. Introduction
• 6.2. Cell-free DNA
• 6.3. Circulating Tumor Cells
• 6.4. Circulating Tumor DNA
• 6.5. Extracellular Vesicles

7. Liquid Biopsy Market, by Sample

• 7.1. Introduction
• 7.2. Blood Based
• 7.3. Urine Based

8. Liquid Biopsy Market, by Type

• 8.1. Introduction
• 8.2. Assay Kits
• 8.3. Instruments
• 8.4. Services

9. Liquid Biopsy Market, by Technology

• 9.1. Introduction
• 9.2. Multi-gene Parallel Analysis using NGS
• 9.3. Single-gene Analysis using PCR Microarrays

10. Liquid Biopsy Market, by Indication

• 10.1. Introduction
• 10.2. Cancer Indication
  • 10.2.1. Breast Cancer
  • 10.2.2. Colorectal Cancer
  • 10.2.3. Lung Cancer
  • 10.2.4. Melanoma
  • 10.2.5. Prostate Cancer
• 10.3. Non-Cancer Indication

11. Liquid Biopsy Market, by End-User

• 11.1. Introduction
• 11.2. Academic & Research Centers
• 11.3. Clinical Diagnostic Laboratories
• 11.4. Hospitals
• 11.5. Physician's Office Laboratories

12. Liquid Biopsy Market, by Application

• 12.1. Introduction
• 12.2. Early Cancer Screening
• 12.3. Recurrence Monitoring
• 12.4. Therapy Selection
• 12.5. Treatment Monitoring

13. Americas Liquid Biopsy Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Liquid Biopsy Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Liquid Biopsy Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Mayo Clinic and Lucence join forces to expand global liquid biopsy access
  • 16.3.2. PanGIA Biotech and Canary Oncoceutics partner to pioneer an AI-integrated urine-based liquid biopsy
  • 16.3.3. QIAGEN expands liquid biopsy automation portfolio
  • 16.3.4. Strand Life Sciences launches liquid biopsy test for improved cancer diagnosis
  • 16.3.5. Novigenix unveils an AI-powered multimodal liquid biopsy approach that integrates cfDNA analysis and mRNA immune profiling
  • 16.3.6. SOPHiA GENETICS partners with the European Liquid Biopsy Society to advance decentralized liquid biopsy solutions
  • 16.3.7. Hitachi High-Tech and Gencurix forge strategic partnership to revolutionize cancer molecular diagnostics through advanced liquid biopsy and digital reporting for personalized treatment decisions
  • 16.3.8. Personalis and Tempus partner to advance precision liquid biopsy diagnostics
  • 16.3.9. Renovaro Biosciences to acquire Cyclomics to transform liquid biopsy technology
  • 16.3.10. Myriad Genetics expands its oncology portfolio by acquiring Precise Tumor and Precise Liquid assays from Intermountain Precision Genomics
  • 16.3.11. Veracyte strengthens liquid biopsy platform with C2i Genomics acquisition
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. F. Hoffmann-La Roche Ltd.
  • 16.4.2. Illumina, Inc.
  • 16.4.3. QIAGEN N.V.
  • 16.4.4. Guardant Health, Inc.

Companies Mentioned

• 1. ANGLE PLC
• 2. Bio-Rad Laboratories, Inc.
• 3. Bio-Techne Corporation
• 4. Biocartis NV
• 5. Danaher Corporation
• 6. DiaCarta, Inc.
• 7. Dxcover Limited
• 8. Epic Sciences Inc.
• 9. Exact Sciences Corporation
• 10. F. Hoffmann-La Roche Ltd.
• 11. GENCURIX
• 12. Guardant Health, Inc.
• 13. Illumina, Inc.
• 14. Labcorp Holdings Inc.
• 15. Laboratory Dr. med. Pachmann
• 16. Lucence Health Inc.
• 17. LungLife AI, Inc.
• 18. MDxHealth SA
• 19. Menarini Silicon Biosystems SpA
• 20. Merck KGaA
• 21. Myriad Genetics, Inc.
• 22. Natera, Inc.
• 23. NeoGenomics Laboratories, Inc.
• 24. OncoDNA SA
• 25. PerkinElmer, Inc.
• 26. Personalis, Inc.
• 27. QIAGEN N.V.
• 28. SAGA Diagnostics AB
• 29. Strand Life Sciences Pvt Ltd.
• 30. Sysmex Corporation
• 31. Tempus AI, Inc.
• 32. Thermo Fisher Scientific Inc.